Farnesyltransferase inihibitors in hematologic malignancies

Blood Reviews

Volumn 21, Issue 4, 2007, Pages 173-182

  Harousseau, Jean Luc ^a  

^a HÔTEL DIEU   (France)

Author keywords

Acute myeloid leukemia; Chronic myeloid leukemia; Farnesyltransferase inhibitor; Lonafarnib; Multiple myeloma; Myelodysplastic syndrome; Tipifarnib

Indexed keywords

ANAGRELIDE; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; BILIRUBIN; BORTEZOMIB; CYTOTOXIC AGENT; DASATINIB; HEMOPOIETIC GROWTH FACTOR; HYDROXYUREA; IMATINIB; LIVER ENZYME; LONAFARNIB; NILOTINIB; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; TIPIFARNIB; VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; ANOREXIA; ARTICLE; ATAXIA; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; CONFUSION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSARTHRIA; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION PROFILING; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOKALEMIA; INFECTION; KIDNEY DYSFUNCTION; LEG PAIN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOID METAPLASIA; NAUSEA; NEUROTOXICITY; OPTIMAL DRUG DOSE; POLYDIPSIA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SIGNAL TRANSDUCTION; SYNCOPE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT PLANNING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HEMATOLOGIC NEOPLASMS; HUMANS; PIPERIDINES; PYRIDINES; QUINOLONES; SIGNAL TRANSDUCTION;

EID: 34249979529     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2006.12.001     Document Type: Article

References (52)

1. End DW, Mevellec L, Angibaud P. Farnesyl protein transferase inhibitors: molecular mechanisms and progress in the clinic. Curr Top Med Chem. In press.
2. End D.W. Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway. Invest New Drugs 17 (1999) 241-258
3. Rowinsky E.K., Windle J.J., and Von Hoff D.D. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol 17 (1999) 3631-3652
4. Boguski M.S., and McCormick F. Proteins regulating Ras and its relatives. Nature 366 (1993) 643-654
5. Khosravi-Far R., Cox A.D., Kato K., and Der C.J. Protein prenylation: key to ras function and cancer intervention?. Cell Growth Differ 3 (1992) 461-469
6. Rodenhuis S. ras and human tumors. Semin Cancer Biol 3 (1992) 241-247
7. Bos J.L. ras oncogenes in human cancer: a review. Cancer Res 49 (1989) 4682-4689
8. Reuter C.W., Morgan M.A., and Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?. Blood 96 (2000) 1655-1669
9. Lancet J.E., and Karp J.E. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood 102 (2003) 3880-3889
10. Burgering B.M., and Coffer P.J. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 376 (1995) 599-602
11. Klippel A., Escobedo M.A., Wachowicz M.S., et al. Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation. Mol Cell Biol 18 (1998) 5699-5711
12. End D.W., Smets G., Todd A.V., et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 61 (2001) 131-137
13. Cox A.D., and Der C.J. Farnesyltransferase inhibitors: promises and realities. Curr Opin Pharmacol 2 (2002) 388-393
14. Feldman E.J. Farnesyltransferase inhibitors in myelodysplastic syndrome. Curr Hematol Rep 4 (2005) 186-190
15. Ganguly A.K., Doll R.J., and Girijavallabhan V.M. Farnesyl protein transferase inhibition: a novel approach to anti-tumor therapy. the discovery and development of SCH 66336. Curr Med Chem 8 (2001) 1419-1436
16. Karp J.E. Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies. Semin Hematol 38 (2001) 16-23
17. Du W., Lebowitz P.F., and Prendergast G.C. Cell growth inhibition by farnesyltransferase inhibitors is mediated by a gain of geranylgeranylated RhoB. Mol Cell Biol 19 (1999) 1831-1840
18. Ashar H.R., James L., Gray K., et al. The farnesyl transferase inhibitor SCH 66336 induces a G(2) - > M or G(1) pause in sensitive human tumor cell lines. Exp Cell Res 262 (2001) 17-27
19. Crespo N.C., Ohkanda J., Yen T.J., Hamilton A.D., and Sebti S.M. The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. J Biol Chem 276 (2001) 16161-16167
20. Lebowitz P.F., Casey P.J., Prendergast G.C., and Thissen J.A. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J Biol Chem 272 (1997) 15591-15594
21. Zujewski J., Horak I.D., Bol C.J., et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 18 (2000) 927-941
22. Korycka A., Smolewski P., and Robak T. The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro. Eur J Haematol 73 (2004) 418-426
23. Mackenzie K.L., Dolnikov A., Millington M., Shounan Y., and Symonds G. Mutant N-ras induces myeloproliferatives disorders and apoptosis in bone marrow repopulated mice. Blood 93 (1999) 2043-2056
24. Karp J.E., Lancet J.E., Kaufmann S.H., et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 97 (2001) 3361-3369
25. Harousseau J.L., Reiffers J., Lowenberg B., et al. Zarnestra (R115777) in patients with relapsed and refractory acute myelogenous leukemia (AML): results of a multicenter phase 2 study. Blood 102 Pt1 (2003) 176a Abstract 614
26. TM) in previously untreated poor-risk AML of the elderly: updated results of a multicenter phase 2 trial. Blood 104 pt1 (2004) 249a Abstract 874
27. TM (tipifarnib, R115777) in relapsed and refractory acute myeloid leukemia. Blood 104 (2004) 246a Abstract 861
28. Zimmerman T.M., Harlin H., Odenike O.M., et al. Dose ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol 22 (2004) 4764-4770
29. Karp J.E., Gojo I., Greer J., et al. Tipifarnib (ZARNESTRA, R115777) as Maintenance Therapy for Adults in Complete Remission (CR) following Induction and Consolidation Therapies for Poor-Risk Acute Myelogenous Leukemia (AML): A Phase II Trial. Blood 106 (2005) 780a Abstract 2783
30. TM) in patients with advanced hematologic malignancies. Blood 100 (2002) 789a Abstract 3120
31. TM) for the treatment of patients with advanced hematologic malignancies: a phase II study. Blood 100 (2002) 793a Abstract 3132
32. Kurzrock R., Kantarjian H.M., Cortes J.E., et al. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood 102 (2003) 4527-4534
33. Kurzrock R., Albitar M., Cortes J.E., et al. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 22 (2004) 1287-1292
34. TM). Blood 104 pt 1 (2004) 23a Abstract 68
35. Kurzrock R., Verstovsek S., Wright J.J., et al. Phase I study using alternate week administration of the farnesyl transferase inhibitor R115777 (Zarnestra) in patients with myelodysplastic syndrome. Blood 104 Pt 1 (2004) 402a Abstract 1436
36. Feldman E.J., Cortes J., Holyoake T.L., et al. Continuous oral lonafarnib (Sarasar) for the treatment of patients with myelodysplastic syndrome. Blood 102 (2003) 421a Abstract 1531
37. Peters D.G., Hoower R.R., Gerlach M.J., et al. Activity of the farnesyl protein transferase inhibitor SCH66336 agains BCR/ABL_induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood 97 (2001) 1404-1412
38. Reichert A., Heisterkamp N., Daley G.Q., and Groffen J. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood 97 (2001) 1399-1403
39. Hoover R.R., Mahon F.X., Melo J.V., and Daley G.Q. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 100 (2002) 1068-1071
40. Nakajima A., Tauchi T., and Ohyashiki K. ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis. Leukemia 15 (2001) 989-990
41. Cortes J., Albitar M., Thomas D., et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid and other hematologic malignancies. Blood 101 (2003) 1692-1697
42. Gotlib J., Mauro M., O'Dwyer M.E., et al. Tipifarnib (ZARNESTRA) and Imatinib (GLEEVEC) combination therapy in patients with advanced chronic myelogenous leukemia (CML): preliminary results of a phase I study. Blood 102 (2003) 909a Abstract 3384
43. Borthakur G., Kantarjian H., Daley G., et al. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer 106 (2006) 346-352
44. Cortes J., Garcia-Manero G., O'Brien S., et al. A phase I study of tipifarnib in combination with imatinib mesylate (IM) for patients (Pts) with chronic myeloid leukemia (CML) in chronic phase (CP) who failed IM therapy. Blood 104 Pt 1 (2004) 176 Abstract 1011
45. Le Gouill S., Pellat-Deceunynck C., Harousseau J.L., et al. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia 16 (2002) 1664-1667
46. Ochiai N., Uchida R., Fuchida S., et al. Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro. Blood 102 (2003) 3349-3353
47. Bolick S.C., Landowski T.H., Boulware D., et al. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. Leukemia 17 (2003) 451-457
48. Beaupre D.M., Cepero E., Obeng E.A., Boise L.H., and Lichtenheld M.G. R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways. Mol Cancer Ther 3 (2004) 179-186
49. Alsina M., Fonseca R., Wilson E.F., et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 103 (2004) 3271-3277
50. David E., Sun S.Y., Waller E.K., Chen J., Khuri F.R., and Lonial S. The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. Blood 106 (2005) 4322-4329
51. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 342 (2000) 1255-1265
52. Mesa R.A., Tefferi A., Gray L.A., Reeder T., Schroeder G., and Kaufmann S.H. In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia. Leukemia 17 (2003) 849-855